Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $22.05
Previous CloseN/A
Volume99.85K
Average Volume (3M)2.60M
Market Cap
$2.24M
Enterprise ValueN/A
Total Cash (Recent Filing)$5.58M
Total Debt (Recent Filing)$10.87M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 08, 2025EPS Estimate
-1.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.54
Shares Outstanding1,173,211
10 Day Avg. Volume108,739
30 Day Avg. Volume2,599,197
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)157.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.33Price Target Upside493.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Evaxion Biotech News
PremiumCompany Announcements
Evaxion Biotech to Present at Key Conferences in 2025
PremiumCompany Announcements
Evaxion Biotech Extends Phase 2 Trial for Cancer Vaccine EVX-01PremiumCompany Announcements
Evaxion Biotech Secures Nasdaq Compliance, Strengthens Financial Position
PremiumCompany Announcements
Evaxion Biotech Expands Capital Through ADS Offering
PremiumMarket News
3 Penny Stocks to Watch Now, 2/6/25---
Bulls Say, Bears Say
Bulls Say
AI TechnologyEvaxion has progressively built not only a set of versatile AI models, but also a strong portfolio of preclinical and clinical candidates allowing for additional value creation.
PartnershipsMerck's decision on option exercise could add to financial strength, as Merck recently increased its stake in Evaxion to nearly 20%.
Bears Say
RisksRisks to the Buy rating include partnership, technology, clinical, regulatory, commercial, legal and intellectual property, competition, and dilution.
---
Ownership Overview
―
Insiders
0.29% Mutual Funds
46.12% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $1.70 and its highest was $22.05 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $2.24M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s upcoming earnings report date is May 08, 2025 which is in 56 days.
How were Evaxion Biotech’s earnings last quarter?
Currently, no data Available
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is -1.96.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 1,173,211 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evaxion Biotech?
Currently, no hedge funds are holding shares in EVAX
---
Company Description
Evaxion Biotech
Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market.
---
EVAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including a transformative agreement with MSD and solid pipeline progress, but also noted challenges with NASDAQ compliance and business development income targets.Read More>---
EVAX Stock 12 Month Forecast
Average Price Target
$11.33
▲(493.19% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
ImmunityBio
―
Allogene Therapeutics
―
Cullinan Management
―
Best Analysts Covering EVAX
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-69.39%
reiterated a buy rating 17 days ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -69.39% per trade.
---